For decades, the search for new vaccine adjuvants has been largely empirical. A series of
new adjuvants and related formulations are now emerging that are acting through identified …

Because of the age-related immune system decline, 2 potentiated influenza vaccines were
specifically licensed for the elderly: Fluad®, an MF59-adjuvanted vaccine administered …

Background Safety data are lacking on influenza vaccination in general and on A (H1N1) v
vaccination in particular in patients with inflammatory bowel disease (IBD) receiving …

Adults over the age of 60‐65 years suffer disproportionally from seasonal influenza,
experiencing high rates of complications, exacerbation of underlying medical comorbidities …

The development of more advanced and effective vaccines is of great interest in modern
medicine. These new-generation vaccines, based on recombinant proteins or DNA, are …

Studies on mice showed that chitosan as an adjuvant for H5 inactivated influenza vaccines
administered intramuscularly enhances significantly antibody titers and protective efficiency …

Vaccination is universally considered as the principal measure for the control of influenza,
which represents a significant burden worldwide, both from a health-care and a socio …

Vaccination has contributed significantly to improving public health by reducing the mortality
caused by a number of infectious diseases. Thanks to extensive childhood vaccination …

The adjuvanted influenza vaccine FLUAD™ is composed of subunit influenza antigens
combined with the MF59-adjuvant emulsion. The vaccine was developed primarily for use in …

We evaluated whether the increased immunogenicity provided by an MF59-adjuvant
influenza vaccine translates into increased protection among the elderly. Residents of 25 …